Related references
Note: Only part of the references are listed.Macrophage Biology and Mechanisms of Immune Suppression in Breast Cancer
Anita K. Mehta et al.
FRONTIERS IN IMMUNOLOGY (2021)
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
Anita K. Mehta et al.
NATURE CANCER (2021)
A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y. Ho et al.
CANCER (2020)
Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance)
Meenakshi Anurag et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach
Yacine Bareche et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer
Scott F. Schoninger et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease
Ioannis Zerdes et al.
MOLECULAR ONCOLOGY (2020)
B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez et al.
NATURE (2020)
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Rita Cabrita et al.
NATURE (2020)
The single-cell pathology landscape of breast cancer
Hartland W. Jackson et al.
NATURE (2020)
B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Ami N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
Zhiwei Hu
SCIENTIFIC REPORTS (2020)
Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?
Triantafyllia Koletsa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Javier Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim results.
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types
Jason Ptacek et al.
LABORATORY INVESTIGATION (2020)
Tim-3 finds its place in the cancer immunotherapy landscape
Nandini Acharya et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial
K. Kalinsky et al.
ANNALS OF ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
TIGIT in cancer immunotherapy
Joe-Marc Chauvin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
Signe Korsgaard Skriver et al.
BREAST CANCER RESEARCH (2020)
Tumour-Infiltrating Immune Cell-Based Subtyping and Signature Gene Analysis in Breast Cancer Based on Gene Expression Profiles
Jingxin Jiang et al.
JOURNAL OF CANCER (2020)
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer
H. Raza Ali et al.
NATURE CANCER (2020)
Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis
Miseon Lee et al.
MODERN PATHOLOGY (2019)
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
Tanja K. Eggersmann et al.
BIODRUGS (2019)
Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
Luca Cassetta et al.
CANCER CELL (2019)
Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity
Takahiro Tsujikawa et al.
CYTOMETRY PART A (2019)
Locally advanced breast cancer: Tumor-infiltrating lymphocytes as a predictive factor of response to neoadjuvant chemotherapy
Leonardo Russo et al.
EJSO (2019)
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Branimir Sikic et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer
Xuefei Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Differences in intra-tumoral macrophage infiltration and radiotherapy response among intrinsic subtypes in pT1-T2 breast cancers treated with breast-conserving surgery
Stina Garvin et al.
VIRCHOWS ARCHIV (2019)
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
Geoffrey T. Gibney et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER plus Breast Cancer Cells
Andres M. Castellaro et al.
CANCERS (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
Johanna Wagner et al.
CELL (2019)
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy
Adrienne G. Waks et al.
CLINICAL CANCER RESEARCH (2019)
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
Sara M. Tolaney et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
Romualdo Barroso-Sousa et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
Yukie Fujimoto et al.
BREAST CANCER (2019)
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Constantia Pantelidou et al.
CANCER DISCOVERY (2019)
Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients
Jingping Yuan et al.
CANCER CELL INTERNATIONAL (2019)
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Anne-Sophie Hamy et al.
CLINICAL CANCER RESEARCH (2019)
Breast cancer statistics, 2019
Carol E. DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer
Michael Sofopoulos et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
Diana C. Marquez-Garban et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2019)
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
Sasagu Kurozumi et al.
SCIENTIFIC REPORTS (2019)
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
T. A. Chan et al.
ANNALS OF ONCOLOGY (2019)
A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients
Hye Won Hwang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Expression of programmed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol
Lukanxuan Wu et al.
GYNECOLOGICAL ENDOCRINOLOGY (2019)
Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer
Yuichiro Miyoshi et al.
ONCOLOGY LETTERS (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Clinical Implications of Tumor-Infiltrating Immune Cells in Breast Cancer
Shi-Chao Zhang et al.
JOURNAL OF CANCER (2019)
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
Bruno Valentin Sinn et al.
BREAST CANCER RESEARCH (2019)
Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors
Robert Wesolowski et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis
Li-Chung Tsao et al.
JCI INSIGHT (2019)
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
Marcelo Sobral-Leite et al.
BREAST CANCER RESEARCH (2019)
Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer
Hong Sik Park et al.
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
Maria Vittoria Dieci et al.
SEMINARS IN CANCER BIOLOGY (2018)
Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
Wataru Goto et al.
ANTICANCER RESEARCH (2018)
Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment
Elham Azizi et al.
CELL (2018)
A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer
Johanna C. Bendell et al.
CLINICAL CANCER RESEARCH (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Tumor-infiltrating lymphocyte volume is a better predictor of neoadjuvant therapy response and overall survival in triple-negative invasive breast cancer
Lin Zhang et al.
HUMAN PATHOLOGY (2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Breast Cancer Biology: Clinical Implications for Breast Radiation Therapy
Janet K. Horton et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer
Darren K. Patten et al.
NATURE MEDICINE (2018)
Quantitative mass imaging of single biological macromolecules
Gavin Young et al.
SCIENCE (2018)
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Zhixian Liu et al.
TRANSLATIONAL ONCOLOGY (2018)
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Jennifer L. Guerriero
TRENDS IN MOLECULAR MEDICINE (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes
Jia-Ren Lin et al.
ELIFE (2018)
Immunological differences between primary and metastatic breast cancer
B. Szekely et al.
ANNALS OF ONCOLOGY (2018)
Tumor-associated macrophages in breast cancer: Innocent bystander or important player?
Si-Qi Qiu et al.
CANCER TREATMENT REVIEWS (2018)
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Javier Cortes et al.
CANCER TREATMENT REVIEWS (2018)
Deep Profiling of Mouse Splenic Architecture with CODEX Multiplexed Imaging
Yury Goltsev et al.
CELL (2018)
HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15
Maria A. Garrido et al.
IMMUNOGENETICS (2018)
A phase II, single arm study assessing the efficacy of pembrolizumab (Pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)
Heather L. McArthur et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Alexandra Thomas et al.
ONCOIMMUNOLOGY (2018)
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival
Marcelo Sobral-Leite et al.
ONCOIMMUNOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers
Takahiro Watanabe et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor positive breast cancers
Uma Krishnamurti et al.
HUMAN PATHOLOGY (2017)
Posttranscriptional Control of PD-L1 Expression by 17β-Estradiol via PI3K/Akt Signaling Pathway in ERα-Positive Cancer Cell Lines
Lingyun Yang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer
Laurence Buisseret et al.
MODERN PATHOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers
Xia Liu et al.
ONCOLOGIST (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (ID01) Inhibitor for Immunooncology
Eddy W. Yue et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
Paola A. Betancur et al.
NATURE COMMUNICATIONS (2017)
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Woosung Chung et al.
NATURE COMMUNICATIONS (2017)
Immunotherapeutic target expression on breast tumors can be amplified by hormone receptor antagonism: a novel strategy for enhancing efficacy of targeted immunotherapy
Ritika Jaini et al.
ONCOTARGET (2017)
Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer
In Hye Song et al.
CANCER RESEARCH AND TREATMENT (2017)
Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis
Takahiro Tsujikawa et al.
CELL REPORTS (2017)
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
Aura Muntasell et al.
FRONTIERS IN IMMUNOLOGY (2017)
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor immunity, immunosuppression, or Bystander Sentinels in Disease?
Emily Jayne Colbeck et al.
FRONTIERS IN IMMUNOLOGY (2017)
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue
David A. Quigley et al.
ONCOIMMUNOLOGY (2017)
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Yuka Asano et al.
BMC CANCER (2017)
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Cinzia Solinas et al.
BREAST (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
UPRegulation of CD47 by the endoplasmic reticulum stress pathway controls anti-tumor immune responses
Katherine L. Cook et al.
BIOMARKER RESEARCH (2017)
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
Vasiliki Pelekanou et al.
BREAST CANCER RESEARCH (2017)
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
H. R. Ali et al.
ANNALS OF ONCOLOGY (2017)
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Shiping Jiao et al.
CLINICAL CANCER RESEARCH (2017)
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2-breast cancer: results from two prospective trials
M. V. Dieci et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
PD-L1 expression in triple negative breast cancer (TNBC) is associated with improved outcomes
M. A. Mardones et al.
CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer
Hee Jin Lee et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
Vassiliki Kotoula et al.
ONCOTARGET (2016)
Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract
Zheng Shen et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2016)
The genomic landscape of breast cancer and its interaction with host immunity
Stephen Luen et al.
BREAST (2016)
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
Gary Middleton et al.
BRITISH JOURNAL OF CANCER (2016)
Endoplasmic Reticulum Stress Protein GRP78 Modulates Lipid Metabolism to Control Drug Sensitivity and Antitumor Immunity in Breast Cancer
Katherine L. Cook et al.
CANCER RESEARCH (2016)
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
Rhiannon K. Beckers et al.
HISTOPATHOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The immune microenvironment of breast ductal carcinoma in situ
Elizabeth Thompson et al.
MODERN PATHOLOGY (2016)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Carsten Denkert et al.
MODERN PATHOLOGY (2016)
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting
Luisa Carbognin et al.
ONCOLOGIST (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling
Hee Jin Lee et al.
ONCOTARGET (2016)
A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases
Xilin Chen et al.
ONCOTARGET (2016)
Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
H. Raza Ali et al.
PLOS MEDICINE (2016)
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention
Catherine Sautes-Fridman et al.
FRONTIERS IN IMMUNOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
Vincent K. Tuohy et al.
CANCERS (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
The biology and function of fibroblasts in cancer
Raghu Kalluri
NATURE REVIEWS CANCER (2016)
Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
Sabrina Rossi et al.
ONCOTARGET (2016)
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H. R. Ali et al.
ANNALS OF ONCOLOGY (2015)
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2015)
A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Rita Nanda et al.
CANCER RESEARCH (2015)
CD47 blockade as another immune checkpoint therapy for cancer
Robert H. Vonderheide
NATURE MEDICINE (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
Huimin Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells
Hui Liu et al.
ONCOLOGY REPORTS (2015)
Prognostic Value of Tumor-Associated Macrophages According to Histologic Locations and Hormone Receptor Status in Breast Cancer
Jae Moon Gwak et al.
PLOS ONE (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer
Piotr Tymoszuk et al.
BMC CANCER (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer
Nicola E. Annels et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Jason R. Brown et al.
CLINICAL CANCER RESEARCH (2014)
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper et al.
CLINICAL CANCER RESEARCH (2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar et al.
LANCET (2014)
Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry
Charlotte Giesen et al.
NATURE METHODS (2014)
Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
Edward C. Stack et al.
METHODS (2014)
Tumor-Associated Macrophages are Correlated with Tamoxifen Resistance in the Postmenopausal Breast Cancer Patients
Qi-jia Xuan et al.
PATHOLOGY & ONCOLOGY RESEARCH (2014)
Tertiary lymphoid structures in cancer and beyond
Marie-Caroline Dieu-Nosjean et al.
TRENDS IN IMMUNOLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Prognostic significance of FOXP3+tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
Shuzhen Liu et al.
BREAST CANCER RESEARCH (2014)
Tumour-infiltrating CD8+lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
A. N. Seo et al.
BRITISH JOURNAL OF CANCER (2013)
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Sylvie Rusakiewicz et al.
CANCER RESEARCH (2013)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
Patrizia Leone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
High-Infiltration of Tumor-Associated Macrophages Predicts Unfavorable Clinical Outcome for Node-Negative Breast Cancer
Yue Zhang et al.
PLOS ONE (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer - A Substudy of the Neoadjuvant GeparQuinto Trial
Yasmin Issa-Nummer et al.
PLOS ONE (2013)
Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer
Chunyan Lan et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2013)
Inflammatory cells in node-negative breast cancer
Britta Lofdahl et al.
ACTA ONCOLOGICA (2012)
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
Catharina Medrek et al.
BMC CANCER (2012)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
Makiko Ono et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells
Keiko Kajitani et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
Yan Liu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
Christiane Sahm et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Tumour-infiltrating macrophages and clinical outcome in breast cancer
S. M. A. Mahmoud et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue: Unusually high frequency of down-regulation in breast cancer tissues
Toshihiko Torigoe et al.
PATHOLOGY INTERNATIONAL (2012)
Leukocyte composition of human breast cancer
Brian Ruffell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Clinical implication of HLA class I expression in breast cancer
Koichi Kaneko et al.
BMC CANCER (2011)
Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer
Ludovic Martinet et al.
CANCER RESEARCH (2011)
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Sylvain Ladoire et al.
JOURNAL OF PATHOLOGY (2011)
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells
Ramon Kaneno et al.
CELLULAR ONCOLOGY (2011)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Hard and soft lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy
Federico Garrido et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease
Eoin F. McKinney et al.
NATURE MEDICINE (2010)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation
G. Solinas et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
Christine Desmedt et al.
CLINICAL CANCER RESEARCH (2008)
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer:: Phase III randomized GeparTrio trial
Gunter von Minckwitz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer
Eiki Kikuchi et al.
CANCER SCIENCE (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma
Hiroshi Kitamura et al.
JOURNAL OF UROLOGY (2007)
Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)
Magdalena J. Polanczyk et al.
INTERNATIONAL IMMUNOLOGY (2007)
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
Andrew E. Teschendorff et al.
GENOME BIOLOGY (2007)
Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5
Tomohide Tsukahara et al.
CANCER SCIENCE (2006)
Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis
J Condeelis et al.
CELL (2006)
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
Z Madjd et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer:: The GEPARDUO Study of the German Breast Group
G von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated
S Demaria et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro
P Correale et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
Share Paper
